Biocept surges on lung cancer tie-up with Quest Diagnostics

Biocept

22/06/2021 13:37

** Shares of oncology diagnostics co Biocept Inc  BIOC.O 
surge ~33% premarket to $5.60- a near three-month high
    ** Stock set for its best day in one year
    ** BIOC announces collaboration with Quest Diagnostics
 DGX.N  to provide BIOC's NGS-based liquid biopsy targeted lung
cancer test to DGX patients  urn:newsml:reuters.com:*:nBw6tt0R3a
    ** The liquid biopsy test is a less invasive lab developed
test used to profile patients with advanced non-small cell lung
cancer
    ** DGX shares unchanged in premarket trade
    ** BIOC down 5.4% YTD

 (Reporting by Ambar Warrick in Bengaluru)
 ((Ambar.Warrick@thomsonreuters.com; +91-80-6182-2837; Reuters
Messaging: ambar.warrick.thomsonreuters.com@reuters.net;
Twitter: @AmbarWarrick))